Newron Pharmaceuticals S.p.A. - Product Pipeline Review - 2015

Published: Jun, 2015 | Pages: 44 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Newron Pharmaceuticals S.p.A. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Newron Pharmaceuticals S.p.A. - Product Pipeline Review - 2015', provides an overview of the Newron Pharmaceuticals S.p.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Newron Pharmaceuticals S.p.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Newron Pharmaceuticals S.p.A. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Newron Pharmaceuticals S.p.A.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Newron Pharmaceuticals S.p.A.'s pipeline products

Reasons to buy

- Evaluate Newron Pharmaceuticals S.p.A.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Newron Pharmaceuticals S.p.A. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Newron Pharmaceuticals S.p.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Newron Pharmaceuticals S.p.A. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Newron Pharmaceuticals S.p.A.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Newron Pharmaceuticals S.p.A. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Newron Pharmaceuticals S.p.A. Snapshot 5
Newron Pharmaceuticals S.p.A. Overview 5
Key Information 5
Key Facts 5
Newron Pharmaceuticals S.p.A. - Research and Development Overview 6
Key Therapeutic Areas 6
Newron Pharmaceuticals S.p.A. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Newron Pharmaceuticals S.p.A. - Pipeline Products Glance 10
Newron Pharmaceuticals S.p.A. - Late Stage Pipeline Products 10
Pre-Registration Products/Combination Treatment Modalities 10
Newron Pharmaceuticals S.p.A. - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Newron Pharmaceuticals S.p.A. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Newron Pharmaceuticals S.p.A. - Drug Profiles 14
safinamide 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
NW-3509 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
priralfinamide 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
sarizotan hydrochloride 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
sNN-0029 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
sNN-0031 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Small Molecules to Block Nav1.7 for Central Nervous System Disorders and Pain 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Small Molecules to Block Voltage-Gated Calcium Channel for Central Nervous System Disorder and Pain 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Newron Pharmaceuticals S.p.A. - Pipeline Analysis 27
Newron Pharmaceuticals S.p.A. - Pipeline Products by Target 27
Newron Pharmaceuticals S.p.A. - Pipeline Products by Route of Administration 28
Newron Pharmaceuticals S.p.A. - Pipeline Products by Molecule Type 29
Newron Pharmaceuticals S.p.A. - Pipeline Products by Mechanism of Action 30
Newron Pharmaceuticals S.p.A. - Recent Pipeline Updates 31
Newron Pharmaceuticals S.p.A. - Dormant Projects 38
Newron Pharmaceuticals S.p.A. - Discontinued Pipeline Products 39
Discontinued Pipeline Product Profiles 39
pruvanserin 39
sarizotan hydrochloride 39
Newron Pharmaceuticals S.p.A. - Company Statement 40
Newron Pharmaceuticals S.p.A. - Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44

List of Tables

Newron Pharmaceuticals S.p.A., Key Information 5
Newron Pharmaceuticals S.p.A., Key Facts 5
Newron Pharmaceuticals S.p.A. - Pipeline by Indication, 2015 7
Newron Pharmaceuticals S.p.A. - Pipeline by Stage of Development, 2015 8
Newron Pharmaceuticals S.p.A. - Monotherapy Products in Pipeline, 2015 9
Newron Pharmaceuticals S.p.A. - Pre-Registration, 2015 10
Newron Pharmaceuticals S.p.A. - Phase II, 2015 11
Newron Pharmaceuticals S.p.A. - Phase I, 2015 12
Newron Pharmaceuticals S.p.A. - Preclinical, 2015 13
Newron Pharmaceuticals S.p.A. - Pipeline by Target, 2015 27
Newron Pharmaceuticals S.p.A. - Pipeline by Route of Administration, 2015 28
Newron Pharmaceuticals S.p.A. - Pipeline by Molecule Type, 2015 29
Newron Pharmaceuticals S.p.A. - Pipeline Products by Mechanism of Action, 2015 30
Newron Pharmaceuticals S.p.A. - Recent Pipeline Updates, 2015 31
Newron Pharmaceuticals S.p.A. - Dormant Developmental Projects,2015 38
Newron Pharmaceuticals S.p.A. - Discontinued Pipeline Products, 2015 39
Newron Pharmaceuticals S.p.A., Subsidiaries 42